631863-51-9

Upstream product

• 83948-53-2 3-bromopropylamine tert-butylcarbamate 
• 95-85-2 2-hydroxy-5-chloro-aniline 
• 631863-48-4 [3-(4-chloro-2-nitro-phenoxy)-propyl]-carbamic acid tert-butyl ester 

Downstream Products

• 1027215-98-0 (3-{4-chloro-2-[3-(1-oxy-benzo[1,2,4]triazin-3-yl)ureido]phenoxy}propyl)carbamic acid tert-butyl ester 
• 1027216-08-5 (3-{4-chloro-2-[3-(1,4-dioxybenzo[1,2.4]triazin-3-yl)ureido]phenoxy}propyl)carbamic acid tert-butyl ester 
• 1005451-31-9 {3-[4-chloro-2-(3-quinoxalin-2-yl-ureido)-phenoxy]-propyl}-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

PHARMACEUTICAL COMPOUNDS

The invention provides compounds of the formulae (1), (2) and (3): (1, 2, 3), or salts, solvates or tautomers thereof; wherein G, A,v, m, Xa, Xb, Xc, Xd, Xe, R2, R3, R4, Ar1, Ar2, R6, R10, R11, R12 and R13 are as defined in the claims. The compounds have activity against various kinases or, in the case of N-oxides, are reduced in hypoxic tissues to give compounds having kinase inhibiting activity.

Chk-1 inhibitors

This invention provides compounds and methods for treating cancer. More particularly, the invention provides compounds that inhibit Chk-1. These compounds potentiate the action of DNA-damaging agents such as chemotherapy and radiation therapy.

Chk-1 inhibitors

Disclosed are novel inhibitors of Chk-1 and methods of using the same for therapy.

DIARYLUREA COMPOUNDS AND DERIVATIVES AS CHK-1 INHIBITORS FOR THE TREATMENT OF CANCER

Disclosed are novel inhibitors of Chk-1 and methods of using the same for therapy.